Public Employees Retirement Association of Colorado Has $16.69 Million Position in Charles River Laboratories International, Inc. $CRL

Public Employees Retirement Association of Colorado raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,558.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,643 shares of the medical research company’s stock after purchasing an additional 78,600 shares during the period. Public Employees Retirement Association of Colorado owned 0.17% of Charles River Laboratories International worth $16,685,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of CRL. Tema Etfs LLC bought a new stake in Charles River Laboratories International during the fourth quarter worth about $26,000. Rothschild Investment LLC raised its holdings in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $42,000. Sfam LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $43,000. Finally, Activest Wealth Management increased its position in Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CRL shares. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Evercore reissued an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Finally, JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $208.50.

Charles River Laboratories International Trading Up 0.7%

Shares of CRL opened at $188.74 on Tuesday. The business’s 50-day moving average price is $173.80 and its 200-day moving average price is $182.57. Charles River Laboratories International, Inc. has a twelve month low of $143.06 and a twelve month high of $228.88. The stock has a market cap of $9.09 billion, a PE ratio of -50.20, a P/E/G ratio of 2.14 and a beta of 1.46. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the prior year, the business posted $2.34 earnings per share. The company’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.04 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.